Nobody suggests that the plethora of regular changes to medicine prices, both increases and decreases, including to ensure ongoing subsidised access, undermines or ‘threatens’ the PBS. Governments respond to external realities that impact the PBS almost monthly. If it has to respond to the MFN threat through pricing policies, who cares? Just do it. The more they deny this reality, the harder it will become.
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
A 'Stronger PBS' makes way for 'We are now in a fight to save the PBS'
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New Zealand last among peers for publicly funded modern medicines
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News -
Early real world data shows improvement in treatment resistant depression
June 24, 2026 - - Latest News -
FDA backs AFT’s injectable iron into Phase 3 study as company targets global scale
June 24, 2026 - - Latest News -
Neurizon presents new mechanistic evidence that NUZ-001 restores proteostasis and supports ALS resilience
June 24, 2026 - - Australian Biotech


